Literature DB >> 19850636

When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type?

S J Kim1, S Y Oh, J Y Hong, M H Chang, D H Lee, J Huh, Y H Ko, Y C Ahn, H-J Kim, C Suh, K Kim, W S Kim.   

Abstract

BACKGROUND: The incidence and risk factors of central nervous system (CNS) invasion is still unclear in extranodal natural killer (NK)/T-cell lymphoma, nasal type. PATIENTS AND METHODS: We analyzed 208 patients to study the clinical features and outcomes of CNS disease in extranodal NK/T-cell lymphoma.
RESULTS: Twelve patients (5.76%, 12/208) experienced CNS disease during treatment or follow-up period (median 11.62 months, range 0.2-123.2 months). The clinical variables associated with CNS disease were Ann Arbor stage III/IV (15.87%, P <0.001), regional lymph node involvement (10.41%, P = 0.006), group III/IV of NK/T-cell lymphoma prognostic index (NKPI; 10.20%, P = 0.003), high/high-intermediate international prognostic index (9.30%, P = 0.072) and extra-upper aerodigestive primary sites (9.75%, P = 0.008). In multivariate analysis, NKPI retained the strongest statistical power to predict CNS disease (P = 0.007, relative risk 9.289, 95% confidence interval 1.828-47.212) in extranodal NK/T-cell lymphoma.
CONCLUSIONS: Despite extranodal NK/T-cell lymphoma frequently involves paranasal sinus, a routine CNS evaluation and prophylaxis do not seem to be necessary in NKPI group I or II patients due to a very low incidence. Nevertheless, CNS prophylaxis should be considered in NKPI groups III and IV.

Entities:  

Mesh:

Year:  2009        PMID: 19850636     DOI: 10.1093/annonc/mdp412

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  18 in total

Review 1.  Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.

Authors:  Bradley M Haverkos; Zenggang Pan; Alejandro A Gru; Aharon G Freud; Rachel Rabinovitch; Meng Xu-Welliver; Brad Otto; Carlos Barrionuevo; Robert A Baiocchi; Rosemary Rochford; Pierluigi Porcu
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

Review 2.  Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial.

Authors:  Kwai Han Yoo; Hyewon Lee; Cheolwon Suh
Journal:  Int J Hematol       Date:  2018-01-22       Impact factor: 2.490

Review 3.  Treatment of localized extranodal NK/T cell lymphoma, nasal type.

Authors:  Seok Jin Kim; Won Seog Kim
Journal:  Int J Hematol       Date:  2010-11-18       Impact factor: 2.490

4.  Peripheral T-Cell Lymphomas Involving the Central Nervous System: A Report From the Czech Lymphoma Study Group Registry.

Authors:  Heidi Mocikova; Robert Pytlík; Katerina Benesova; Andrea Janikova; Juraj Duras; Alice Sykorova; Katerina Steinerova; Vit Prochazka; Vit Campr; David Belada; Marek Trneny
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

Review 5.  Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?

Authors:  Chan Yoon Cheah; John F Seymour
Journal:  Curr Oncol Rep       Date:  2015-06       Impact factor: 5.075

Review 6.  Current and future management of NK/T-cell lymphoma based on clinical trials.

Authors:  Motoko Yamaguchi
Journal:  Int J Hematol       Date:  2012-10-17       Impact factor: 2.490

7.  Central nervous system involvement in T-cell lymphoma: A single center experience.

Authors:  Ronit Gurion; Neha Mehta; Jocelyn C Migliacci; Andrew Zelenetz; Alison Moskowitz; Matthew Lunning; Craig Moskowitz; Paul Hamlin; Steven Horwitz
Journal:  Acta Oncol       Date:  2016-04-04       Impact factor: 4.089

8.  Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma.

Authors:  J H Yi; J H Kim; K K Baek; T Lim; D J Lee; Y C Ahn; K Kim; S J Kim; Y H Ko; W S Kim
Journal:  Ann Oncol       Date:  2011-01-10       Impact factor: 32.976

Review 9.  Central Nervous System Involvement of Natural Killer and T Cell Neoplasms.

Authors:  Ashley E Aaroe; Kathryn S Nevel
Journal:  Curr Oncol Rep       Date:  2019-03-27       Impact factor: 5.945

Review 10.  Imaging of sinonasal tumours.

Authors:  Heidi B Eggesbø
Journal:  Cancer Imaging       Date:  2012-05-07       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.